Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Tower Three Partners Announces Controlling Investment in Nurse Assist, LLC

Kevin Seifert Named Chief Executive Officer of Nurse Assist

Tower Three Partners (“Tower Three”), a leading operationally-oriented private equity firm that invests in a concentrated portfolio of U.S.-based middle market companies, today announced that it has made a controlling investment in Nurse Assist, LLC (“Nurse Assist” or the “Company”), a privately-held, certified and FDA-registered manufacturer of medical devices and products that help improve the quality of care and life for patients.

In connection with the investment, Kevin Seifert has assumed the role of Chief Executive Officer of Nurse Assist. Nurse Assist’s founder and previous CEO, Kevin Kile, will remain on the Company’s Board of Directors.

Founded in 1999 and headquartered in Haltom City, Texas, Nurse Assist is a fully-integrated medical device manufacturer focused on providing the highest quality of products and services to patients across the world. With superior quality, low-cost and consistent manufacturing capabilities, Nurse Assist has established itself as an innovative leader in the production of United States Pharmacopeia (USP) sterile water and normal saline. The Company’s products currently extend to four principal categories of medical devices, including USP water and saline and infusion care products, convenience kits, interconnecting cables and patient safety. With significant investment in automation and product development and an established platform in the dynamic and emerging pre-filled syringe market, the Company is well-positioned to meet the needs of its customers in the expanding senior population and continue on its trajectory of growth and strong performance.

Kevin Seifert, Chief Executive Officer of Nurse Assist, said, “As Nurse Assist continues to expand its operations and gain market share as a full-service provider of leading and trusted medical devices, including our USP sterile water and saline pre-filled syringe business, we will work aggressively to scale our business and expand distribution while leveraging our strong customer relationships and product development capabilities. With a loyal customer base, best-in-class manufacturing and an experienced management team, our fully-integrated business is uniquely positioned to capture the compelling infusion care product and patient care market opportunities ahead.”

Kevin Kile said, “We are thrilled to partner with Tower Three as Nurse Assist enters its next phase of growth servicing multiple high-volume, fast-growth markets. With automated production and in-house capabilities to maintain high capacity and quality, Nurse Assist is built on integrated manufacturing, from concept and design to validation and verification. I am confident our stakeholders – including customers, patients and employees – will benefit from Tower Three’s experience and expertise in helping companies broaden their infrastructure, strengthen operations and create greater scale as Nurse Assist continues to increase capacity and drive growth.”

William D. Forrest, Managing Partner of Tower Three, said, “We see enormous long-term potential in Nurse Assist and believe this is the ideal time to facilitate accelerated growth of a proven business. With this investment, Tower Three will leverage our deep operational experience and capital to help Nurse Assist build on its existing market position and further establish itself as a leading medical device provider. With Tower Three’s support, we are confident that Nurse Assist’s outstanding management team, led by Kevin Seifert, will capitalize on the Company’s tremendous market opportunities and continue to drive growth and profitability across the business.”

Terms of the transaction, which was completed in June 2018, were not disclosed.